Improved Therapeutic Responses in a Xenograft Model of Human B Lymphoma (Namalwa) for Liposomal Vincristine versus Liposomal Doxorubicin Targeted via Anti-CD19 IgG2a or Fab′ Fragments

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 1100-1111

  Sapra, Puja ^a   Moase, Elaine H ^a   Ma, Jie ^a,b   Allen, Theresa M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIBODY; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G2A; IMMUNOLIPOSOME; LIPOSOME; MONOCLONAL ANTIBODY; TETRAZOLIUM; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG TARGETING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN G; INHIBITORY CONCENTRATION 50; LIPOSOMES; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; TETRAZOLIUM SALTS; THIAZOLES; TIME FACTORS; VINCRISTINE;

EID: 1042290308     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0041     Document Type: Article

References (67)

1. Gabizon, A., and Papahadjopoulos, D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA, 85: 6949-6953, 1988.
2. Allen, T. M., Newman, M. S., Woodle, M. C., Mayhew, E., and Uster, P. S. Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int. J. Cancer, 62: 199-204, 1995.
3. Ahmad, I., and Allen, T. M. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res., 52: 4817-4820, 1992.
4. Lee, R. J., and Low, P. S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta, 1233: 134-144, 1995.
5. Park, J. W., Hong, K., Kirpotin, D. B., Meyer, O., Papahadjopoulos, D., and Benz, C. C. Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett., 118: 153-160, 1997.
6. Maruyama, K., Takahashi, N., Tagawa, T., Nagaike, K., and Iwatsuru, M. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett., 413: 177-180, 1997.
7. Lopes de Menezes, D. E., Pilarski, L. M., and Allen, T. M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res., 58: 3320-3330, 1998.
8. Pagnan, G., Montaldo, P. G., Pastorino, F., Chiesa, L., Raffaghello, L., Kirchmeier, M., Allen, T. M., and Ponzoni, M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer, 81: 268-274, 1999.
9. Sugano, M., Egilmez, N. K., Yokota, S. J., Chen, F. A., Harding, J., Huang, S. K., and Bankert, R. B. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res., 60: 6942-6949, 2000.
10. Moreira, J. N., Hansen, C. B., Gaspar, R., and Allen, T. M. A growth factor antagonist as a targeting agent for sterically stabilized liposomes in human small cell lung cancer. Biochim. Biophys. Acta, 1514: 303-317, 2001.
11. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U. B., Marks, J. D., Moore, D., Papahadjopoulos, D., and Benz, C. C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 8: 1172-1181, 2002.
12. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2: 750-763, 2002.
13. Allen, T. M., and Moase, E. H. Therapeutic opportunities for targeted liposomal drug delivery. Adv. Drug Delivery Rev., 21: 117-133, 1996.
14. Lopes de Menezes, D. E., Kirchmeier, M. J., Gagne, J-F., Pilarski, L. M., and Allen, T. M. Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells. J. Liposome Res., 9: 199-228, 1999.
15. Sapra, P., and Allen, T. M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res., 62: 7190-7194, 2002.
16. Pietras, R. J., Fendly, B. M., Chazin, V. R., and Pergram, M. D. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
17. Ghetie, M-A., Ghetie, V., and Vitetta, E. S. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin. Cancer Res., 5: 3920-3927, 1999.
18. Bradbury, L. E., Kansas, G. S., Levy, S., Evans, R. L., and Tedder, T. F. The CD19/CD21 signal transducing complex of human B-lymphocytes includes the target of antiproliferative antibody-1 and leu-13 molecules. J. Immunol., 149: 2841-2850, 1992.
19. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu-overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
20. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
21. Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., and Bonavida, B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm., 12: 177-186, 1997.
22. Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S., and Allen, T. M. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta, 1239: 133-144, 1995.
23. Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., and Morgan, A. C. Human anti-mouse immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res., 48: 879-885, 1985.
24. Phillips, N. C., and Dahman, J. Immunogenicity of immunoliposomes: reactivity against species-specific IgG and liposomal phospholipids. Immunol. Lett., 45: 149-152, 1995.
25. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer, 1: 118-129, 2001.
26. Aragnol, D., and Leserman, L. Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc. Natl. Acad. Sci. USA, 83: 2699-2703, 1986.
27. Maruyama, K., Holmber, E., Kennel, S. J., Klibanov, A., Torchilin, V., and Huang, L. Characterization of in vivo immunoliposome targeting to pulmonary endothelium. J. Pharm. Sci., 79: 978-984, 1990.
28. Harding, J. A., Engbers, C. M., Newman, M. S., Goldstein, N. I., and Zalipsky, S. Immunogenicity and pharmacokinetic attributes of poly(ethyleneglycol)-grafted immunoliposomes. Biochim. Biophys. Acta, 1327: 181-192, 1997.
29. Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 88: 11460-11464, 1991.
30. Huang, S. K., Lee, K. D., Hong, K., Friend, D. S., and Papahadjopoulos, D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res., 52: 5135-5143, 1992.
31. Scherphof, G. L., Kamps, J. A. A. M., and Koning, G. A. In vivo targeting of surface-modified liposomes to metastatically growing colon carcinoma cells and sinusoidal endothelial cells in the rat liver. J. Liposome Res., 7: 419-432, 1997.
32. Martin, F. J., Hubbell, W. I., and Papahadjopoulos, D. Immunospecific targeting of liposomes to cells: a novel and efficient method for covalent attachment of Fab′ fragments via disulfide bonds. Biochemistry, 20: 4229-4238, 1981.
33. Martin, F. J., and Papahadjopoulos, D. Irreversible coupling of immunoglobulin fragments to preformed vesicles. An improved method for liposome targeting. J. Biol. Chem., 257: 286-288, 1982.
34. Pastorino, F., Brignole, C., Marimpietri, D., Sapra, P., Moase, E., Allen, T. M., and Ponzoni, M. Doxorubicin-loaded Fab′ fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res., 63: 86-92, 2003.
35. Boman, N. L., Masin, D., Mayer, L. D., Cullis, P. R., and Bally, M. B. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res., 54: 2830-2833, 1994.
36. Gelmon, K. A., Tolcher, A., Diab, A. R., Bally, M. B., Embree, L., Hudon, N., Dedhar, C., Ayers, D., Eisen, A., Melosky, B., Burge, C., Logan, P., and Mayer, L. D. Phase I study of liposomal vincristine. J. Clin. Oncol., 17: 697-705, 1999.
37. Sarris, A. H., Hagemeister, F., Romanguera, J., Rodriguez, M. A., McLaughlin, P., Tsimberidou, A. M., Medeiros, L. J., Samuels, B., Pate, O., Oholendt, M., Kantarjian, H., Burge, C., and Cabanillas, F. Liposomal vinicristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing Phase II trial. Ann. Oncol., 11: 69-72, 2000.
38. Northfelt, D. W., Dezube, B. J., Thommes, J. A., Levine, R., Von Roenn, J. H., Dosik, G. M., Rios, A., Krown, S. E., DuMond, C., and Mamelok, R. D. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol., 15: 653-659, 1997.
39. Muggia, F., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., Burnett, A., Greco, F. A., Morrow, C. P., Paradiso, L. J., and Liang, L-J. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol., 15: 987-993, 1997.
40. 2. Ann. Oncol., 11: 1029-1033, 2000.
41. Lopes de Menezes, D. E., Pilarski, L. M., Belch, A. R., and Allen, T. M. Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo. Biochim. Biophys. Acta, 1466: 205-220, 2000.
42. Allen, T. M., Hansen, C. B., Martin, F., Redemann, C., and Yau-Young, A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta, 1066: 29-36, 1991.
43. Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W-L., Carter, P., Benz, C. C., and Papahadjopoulos, D. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36: 66-75, 1997.
44. Zola, H., Macardle, P. J., Bradford, T., Weedon, H., Yasu, H., and Kurosawa, Y. Preparation and characterization of a chimeric CD19 monoclonal antibody. Immunol. Cell Biol., 69: 411-422, 1991.
45. Iden, D. L., and Allen, T. M. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion technique. Biochim. Biophys. Acta, 1513: 207-216, 2001.
46. Yamaguchi, Y., Kim, H., Kato, K., Masuda, K., Shimada, I., and Arata, Y. Proteolytic fragmentation with high specificity of mouse immunoglobulin G. J. Immunol. Methods, 181: 259-267, 1995.
47. Mayer, L. D., Bally, M. B., Loughrey, H., Masin, D., and Cullis, P. R. Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res., 50: 575-579, 1990.
48. Bartlett, G. R. Phosphorus assay in column chromatography. J. Biol. Chem., 234: 466-468, 1959.
49. Bolotin, E. M., Cohen, R., Bar, L. K., Emanuel, S. N., Lasic, D. D., and Barenholz, Y. Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J. Liposome Res., 4: 455-479, 1994.
50. Harasym, T. O., Cullis, P. R., and Balley, M. B. Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphaticdylcholine/cholesterol liposomes. Cancer Chemother. Pharmacol., 40: 309-317, 1997.
51. Parr, M. J., Masin, D., Cullis, P. R., and Bally, M. B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharmacol. Exp. Ther., 280: 1319-1327, 1997.
52. Webb, M. S., Logan, P., Kanter, P. M., St.-Onge, G., Gelmon, K., Harasym, T., Mayer, L. D., and Bally, M. B. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother. Pharmacol., 42: 461-470, 1998.
53. Allen, T. M. Liposomes in the therapy of infectious diseases and cancer. In: UCLA Symposium on Molecular and Cellular Biology, pp. 405-415. New York: Alan R. Liss, 1988.
54. Webb, M. S., Harasym, T. O., Masin, D., Bally, M. B., and Mayer, L. D. Sphingomyelin cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer, 72: 896-904, 1995.
55. Uckun, F. M., Jaszcz, W., Ambrus, J. L., Fauci, A. S., Gajl-Peczalska, K., Song, S. W., Wick, M. R., Myers, D. E., Waddick, K., and Ledbetter, J. A. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood, 71: 13-29, 1988.
56. Press, O. W., Farr, A. G., Borroz, K. I., Andersen, S. K., and Martin, P. J. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res., 49: 4906-4912, 1989.
57. van Oosterhout, Y. V., van den Herik-Oudijk, I. E., Wessels, H. M., de Witte, T., van de Winkel, J. G., and Preijers, F. W. Effect of isotype on internalization and cytotoxicity of CD19-ricin A immunotoxins. Cancer Res., 54: 3527-3532, 1994.
58. Ishida, T., Kirchmeier, M. J., Moase, E. H., Zalipsky, S., and Allen, T. M. Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim. Biophys. Acta, 1515: 144-158, 2001.
59. Kirchmeier, M. J., Ishida, T., Chevrette, J., and Allen, T. M. Correlations between the rate of intracellular release of endocytosed liposomal doxorubicin and cytotoxicity as determined by a new assay. J. Liposome Res., 11: 15-29, 2001.
60. Jackson, D. V., Jr., and Bender, R. A. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Res., 39: 4346-4349, 1979.
61. Mayer, L. D., Nayar, R., Thies, R. L., Boman, N. L., Cullis, P. R., and Bally, M. B. Identification of vesicle properties that enhance the antitumor activity of liposomal vincristine against murine L1210 leukemia. Cancer Chemother. Pharmacol., 33: 17-24, 1993.
62. Jackson, D. V., Jr., Jobson, V. W., Homesley, H. D., Welander, C., Hire, E. A., Pavy, M. D., Votaw, M. L., Richards, F., II, and Muss, H. B. Vincristine infusion in refractory gynecologic malignancies. Gynecol. Oncol., 25: 212-216, 1986.
63. Jackson, D. V., White, D. R., Spurr, C. L., Hire, E. A., Pavy, M. D., Robertson, M., Legos, H. C., and McMahan, R. A. Moderate-dose vincristine infusion in refractory breast cancer. Am. J. Clin. Oncol., 9: 376-378, 1986.
64. Allen, T. M., Ahmad, I., Lopes de Menezes, D. E., and Moase, E. H. Immunoliposome-mediated targeting of anti-cancer drugs in vivo. Biochem. Soc. Trans., 23: 1073-1079, 1995.
65. Moase, E., Qi, W., Ishida, T., Gabos, Z., Longenecker, B. M., Zimmermann, G. L., Ding, L., Krantz, M., and Allen, T. M. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta, 1510: 43-55, 2001.
66. Moreira, J. N., Gaspar, R., and Allen, T. M. Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim. Biophys. Acta, 1515: 167-176, 2001.
67. Weinstein, J. N., and van Osdol, W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier." Cancer Res., 52: 2747-2751, 1992.